Akari Therapeutics announces granting of patent protection in India

Akari Therapeutics (AKTX) announced the Intellectual Property India has issued Patent No. 562,919 titled, “Thailanstatin Analogs”. The issued patent covers claims for the Company’s potent immuno-oncology PH1 payload, proprietary non-cleavable and cleavable linkers and ADC technology which has applications across various cancer targets.The issued India patent is a divisional patent of the Company’s R&D toxin portfolio on PH1 and builds on the portfolio of previously issued patents. Grant Patent right for PCT/US2018/051721 family was issued by China National Intellectual Property Administration in August 2023, and in Israel in September 2023. Corresponding foreign patent applications are pending and currently undergoing examination in Patent Cooperation Treaty countries – Brazil, Canada, member states of the European Patent Organisation, Hong Kong, Japan, New Zealand, Singapore, & South Africa.